ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Citeline Unveils Trialtrove+ and Sitetrove+

NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- For over two decades, Citeline’s Trialtrove and Sitetrove have been trusted by clinical trial professionals worldwide to power smarter decisions with unparalleled data. Today, Citeline announces the launch of Trialtrove+ and Sitetrove+, with new features and enhancements that elevate use of its gold-standard data to a whole new level.

The “plus” in Trialtrove+ and Sitetrove+ represents a broad set of new features designed to create additional efficiencies for clinical researchers, sponsors and planners, including:

  • Proprietary performance data: Trial, site and country performance metrics enable users to make data-backed decisions.
  • AI chatbot integration: Ella is an intuitive assistant that surfaces answers faster and with precision.
  • Enhanced usability: The intuitive interface transforms searches of Citeline’s robust database — leveraging over 60,000 data sources — into actionable insights.
  • Innovative tools: From a trial health calculator to site comparison capabilities and a KOL-focused Expert Finder, these solutions are built to answer clinical teams’ most pressing questions with unprecedented speed and accuracy.
  • Advanced analytics: Tracking of key trends coupled with intuitive insights enable users to benchmark and answer critical questions for accelerated decision-making.

This game-changing innovation represents a shift from data discovery to true intelligence, unlocking the potential to save time and resources while improving trial success rates.

“It’s a new era for Citeline,” said Christina Masturzo, Vice President of Product at Citeline. “This is the biggest leap forward in clinical trial planning we’ve ever delivered. With Trialtrove+ and Sitetrove+, we’re not just expanding our datasets; we’re transforming the way our clients approach trial planning by integrating deeper insights, smarter tools and a user experience that saves countless hours.

“In an increasingly competitive and complex clinical landscape, our clients need tools that do more than deliver data; they need solutions that empower them to act decisively and strategically,” said Masturzo. “Trialtrove+ and Sitetrove+ provide the clarity, confidence and control they need to navigate these challenges and succeed.”

For more information, visit Citeline.com/plus.

About Citeline

Citeline, a Norstella company, powers a full suite of complementary business intelligence offerings to meet the evolving needs of life science professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial and regulatory-related decisions and create real-world opportunities for growth. 

Citeline’s global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts and more. For more information on one of the world’s most trusted health science partners, visit Citeline and follow on LinkedIn and X

Citeline PR contact:
Diffusion PR for Citeline
norstella@diffusionpr.com
213-318-4500


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  238.38
+4.73 (2.02%)
AAPL  260.48
-0.01 (-0.00%)
AMD  245.04
+8.40 (3.55%)
BAC  52.54
-0.17 (-0.32%)
GOOG  315.72
-0.65 (-0.21%)
META  629.86
+1.47 (0.23%)
MSFT  370.87
-2.20 (-0.59%)
NVDA  188.63
+4.72 (2.57%)
ORCL  138.09
+0.23 (0.17%)
TSLA  348.95
+3.33 (0.96%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.